$Prospective phase 2 trial of daratumumab with dexamethasone in patients with relapsed/refractory multiple myeloma and severe renal impairment or on dialysis: The DARE study$

Prospective phase 2 trial of daratumumab with dexamethasone in patients with relapsed/refractory multiple myeloma and severe renal impairment or on dialysis: The DARE study

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	American journal of hematology 2023-09, Vol.98 (9), p.E226-E229
Hauptverfasser:	Kastritis, Efstathios, Terpos, Evangelos, Symeonidis, Argiris, Labropoulou, Vasiliki, Delimpasi, Sosana, Mancuso, Katia, Zamagni, Elena, Katodritou, Eirini, Rivolti, Elena, Kyrtsonis, Marie‐Christine, Roussou, Maria, Fotiou, Despina, Theodorakakou, Foteini, Ntanasis‐Stathopoulos, Ioannis, Hatjiharissi, Evdoxia, Kanellias, Nikolaos, Migkou, Magdalini, Cheliotis, Giorgos, Manousou, Kyriaki, Gavriatopoulou, Maria, Dimopoulos, Meletios A.
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Combined Chemotherapy Protocols - adverse effects Bortezomib - therapeutic use Dexamethasone Dexamethasone - adverse effects Dialysis Hematology Humans Immunotherapy Monoclonal antibodies Multiple myeloma Multiple Myeloma - drug therapy Neoplasm Recurrence, Local - drug therapy Prospective Studies Renal Dialysis Steroids Targeted cancer therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:
ISSN:	0361-8609 1096-8652
DOI:	10.1002/ajh.27001